Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

Video

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.

“The big advantage of the Tmod technology is that it's a way to selectively target cancer cells. And again, this approach is so unique in the way that in the same construct, you are able to modulate this expression: you're able to have a blocker and you are able to have an activator to use depending on what the cancer cells express.”

Data on the observational BASECAMP-1 study and preclinical data on Tmod chimeric antigen receptor (CAR) T-cell therapies were presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 10-14, 2021, by Julian Molina, MD, PhD, professor, oncology, Mayo Clinic.

Mayo Clinic and A2 Biotherapeutics are partnering to develop mesothelin (MSLN) and carcinoembryonic antigen (CEA)-targeted TmodCAR T-cell therapies. Preclinical data has demonstrated the technology’s robust protective effect on surrogate normal human cells in vitro, even in mixed-cell populations, while also yielding a robust cytotoxic effect on tumor cells in xenograft models.

The BASECAMP-1 study is being conducted to identify patients with relapsed solid tumors with human leukocyte antigen (HLA) loss of heterozygosity (LOH) as a future target for Tmod cell therapy.

GeneTherapyLive spoke with Molina to learn more about Tmod technology and how it compares to other T-cell therapies. He discussed advantages of the technology in solid tumors.

REFERENCES
1. A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021. News release. A2 Bio Therapeutics. November 1, 2021. https://www.businesswire.com/news/home/20211101005077/en/A2-Bio-to-Highlight-Program-Updates-in-Two-Presentations-at-SITC-2021
2. Molina J, Go W, Kopetz S, et al. BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy. Presented at: 2021 SITC Annual Meeting; November 10-14, 2021; Washington, DC. Abstract 491.
Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.